Abeona’s momentum continues as work on NEO facility begins

Story excerpt provided by Crain’s Cleveland Business.

Written by Lydia Coutré.

Abeona Therapeutics hopes to be creating life-saving treatments out of its own manufacturing facility next year.

The clinical-stage biopharmaceutical company, which focuses on developing novel gene and cell therapies for life-threatening rare diseases, held a ceremony earlier this month for the start of construction on a commercial gene therapy manufacturing facility — believed to be the first in Ohio.

The 6,000-square-foot Elisa Linton Center for Rare Disease Therapies, housed within the offices where Abeona is located in the Health-Tech Corridor on Cleveland’s eastern rim, will be built out and validated over the next year. The center is named for Elisa Linton, who was born with Sanfilippo syndrome, a rare genetic condition that causes fatal brain damage.

Abeona, which has offices in New York, Dallas and Cleveland, has been hiring about a person per month, and CEO Tim Miller expects that pace to continue for the next 12 to 18 months as manufacturing ramps up. Moreover, the new center comes at a time when Abeona is experiencing significant growth and has three ongoing clinical trials, two of which are late-stage.

Click here to read the complete article.

Originally published October 28, 2017.